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The mortality from transitional cell carcinoma (TCC) of the urinary bladder increases significantly with the progression of superficial
or locally invasive disease (pTa/pT1) to detrusor muscle-invasive disease (pT2þ). The most common prognostic markers in clinical
use are tumour stage and grade, which are subject to considerable intra- and interobserver variation. Polysomy 17 and HER2/neu
gene amplification and protein overexpression have been associated with more advanced disease. Standardised techniques of
fluorescence in situ hybridisation and immunohistochemistry, which are currently applied to other cancers with a view to offering anti-
HER2/neu therapies, were applied to tumour pairs comprising pre- and postinvasive disease from 25 patients undergoing treatment
for bladder cancer. In the preinvasive tumours, increased HER2/neu copy number was observed in 76% of cases and increased
chromosome 17 copy number in 88% of cases, and in the postinvasive group these values were 92 and 96%, respectively (not
significantly different P¼0.09 and 0.07, respectively). HER2 gene amplification rates were 8% in both groups. Protein overexpression
rates were 76 and 52%, respectively, in the pre- and postinvasive groups (P¼0.06). These results suggest that HER2/neu
abnormalities occur prior to and persist with the onset of muscle-invasive disease. Gene amplification is uncommon and other
molecular mechanisms must account for the high rates of protein overexpression. Anti-HER2/neu therapy might be of use in the
treatment of TCC.
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Transitional cell carcinoma (TCC) of the urinary bladder is
common in the UK, with over 15000 new cases being diagnosed
annually. The low mortality from superficial disease contributes to
this being the second most prevalent cancer in the UK population.
However, with the development of detrusor muscle invasion,
mortality rates increase significantly, and over 50% of patients
already have micrometastasis on diagnosis of detrusor muscle-
invasive disease. Therefore, more aggressive clinical treatment
needs to be applied, if there is a curative aim, in the form of radical
surgery or radiotherapy plus adjuvant treatment (Skinner et al,
1991). Approximately 10–15% of superficial or locally invasive
(pTa/pT1) tumours progress to muscle invasion, and this risk is
dependent on tumour stage and grade. For example, well-
differentiated (grade 1) tumours progress in only 2% of cases,
whereas poorly differentiated (grade 3) tumours progress in up to
20% of cases. However, stage and grade are subject to 50% inter-
and intraobserver variation (van der Meijden et al, 2000).
Therefore, more accurate prognostic factors are desirable, and
genetic markers might fulfil this role (Reznikoff et al, 2000).
Polysomy 17 in TCC is a chromosome-specific event, indepen-
dent of tumour polyploidy (Bartlett et al, 1999) and is associated
with higher tumour stages and grades as well as disease recurrence,
progression and decreased patient survival (Bartlett et al, 1998; Li
et al, 1998; Watters et al, 2000). Polysomy 17 has been observed in
10% of grade 1 and 43% of grade 3 tumours (Watters et al, 2000)
and 32% of pTa/T1 and 72% of pT2 tumours (Li et al, 1998). Gain
of chromosome 17 may therefore be a useful marker of tumour
progression.
The HER2/neu oncogene is located on chromosome 17 q11-21
and encodes for a tyrosine kinase trans-membrane growth factor
receptor. Activation of the HER2/neu receptor, following autopho-
sphorylation of the tyrosine kinase residues results in the
activation of a cascade of intracellular proteins. Ultimately, the
mitotic activity and metastatic potential of the cell increases
(Underwood et al, 1995; Tzahar et al, 1996; Olayioye et al, 2000).
HER2/neu protein overexpression, assessed by immunohisto-
chemistry (IHC), has been associated with increased tumour grade
in TCC, but there is a wide variation in the literature of 2–50%
(Wright et al, 1990; Coombs et al, 1991; McCann et al, 1990;
Underwood et al, 1995; Mellon et al, 1996). This may be due to the
application of different antibodies and scoring systems. Similarly,
although HER2/neu gene amplification rates are higher in muscle-
invasive disease compared with superficial disease, there is a wide
variation in the literature of 4–32% (Coombs et al, 1991;
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yUnderwood et al, 1995; Mellon et al, 1996). Accurate assessment of
the prognostic significance of HER2 in the progression of bladder
cancer requires standardisation of the laboratory techniques.
Current UK guidelines recommend the use of IHC, with the use of
specific antibodies and scoring systems to assess protein over-
expression, and fluorescence in situ hybridisation (FISH) to assess
gene amplification. Our centre is one of the designated centres in
the UK that has the facilities to apply such techniques (Ellis et al,
2000). This is particularly important if the HER2/neu oncogene is
to be targeted with one of the various anti-HER2/neu therapies
being used in the treatment of other cancers. In breast cancer,
tumours that have evidence of HER2/neu gene amplification, or
strong protein overexpression respond to treatment with the anti-
HER2/neu monoclonal antibody Trastuzumab (Herceptin, Gnene-
tech Inc San Francisco, USA). Response rates of 50% have been
observed in combination with chemotherapy and 26% as
monotherapy in women with metastatic breast cancer as well as
an increased time to progression (Slamon et al, 2001; Vogel et al,
2001).
The aim of the present study was to assess HER2/neu protein
overexpression and gene amplification in 25 tumour pairs. The
first tumour of the pair was pre (muscle) invasive and the second
tumour (from the same patient) was postinvasive.
MATERIALS AND METHODS
Patients
Patients with tumours that had progressed from superficial disease
(pTa/pT1) to muscle-invasive disease (pT2) were identified from a
bladder cancer database in the Department of Surgery, Glasgow
Royal Infirmary. In order to assess HER2 abnormalities during
disease progression to muscle invasive disease, pTa/pT1 and pT2
tumours from the same patient were compared. All patients had
full clinical follow-up (age, date of diagnosis, cystoscopic follow-
up, tumour stage and grade and survival). Ethical approval was
obtained for these studies. (5mg) Sections of formalin-fixed
paraffin tissue were cut onto sialinised slides and baked at 561C
overnight. All representative TCCs analysed had one section
stained with haematoxylin and eosin (H&E), and were restaged
and regraded by a specialist urological pathologist (KMG). The
pathologist rejected 52 tumours initially selected for the study
because of the absence of detrusor muscle in either the pre- or
postinvasive tumour. In order to be accepted for the study, both
pre- and postinvasive tumours had to have detrusor muscle in
both specimens.
Fluorescence in situ hybridisation
The FISH methodology was followed as outlined: tissue sections
were dewaxed and rehydrated, then subject to pretreatments with
0.2 N HCL for 20min at room temperature, 8% sodium thiosul-
phate at 801C for 30min, and 0.5% pepsin in 0.01 N HCL for 26min
at 371C. Tissue sections were postfixed in 10% neutral buffered
formalin at room temperature for 10min before dehydration in
ascending grades of alcohol and air drying. These steps were
carried out on a VP2000 robotic pretreatment slide processor
(Vysis, UK, Ltd). The tissue sections were assessed for the extent of
tissue digestion (Watters et al, 2000). Tissue sections were
denatured in 70% formamide, 2  SSC, pH 7–8 at 721C for
5min on the Omnislide hybridisation module (Hybaid, UK, Ltd).
Probes for the pericentromeric region of chromosome 17
(SpectrumGreent) and the locus specific probe for HER2
(SpectrumOranget) were used. For each section, 1ml of each
probe was added to 7ml hybridisation mix (50% formamide, 2 
SSC, 10% dextran sulphate) and 1ml deionised water and
denatured in a water bath at 721C for 5min and then hybridised
overnight at 371C. Posthybridisation washes were in 0.4 SSC,
Nonidet 30, pH 7, at 721C for 2min. The sections were mounted in
0.25mgml
 1 DAPI antifade (Veactashield, UK) and viewed with a
Leica DMLB microscope. A triple band pass filter block spanning
the excitation and emission wavelengths of the SpectrumOranget
and SpectrumGreent and DAPI was used in the analysis of the
hybridisation. Image capture was achieved using a digital camera
(Leica DC 200, Leica, UK).
Fluorescence in situ hybridisation scoring
Serially sectioned haemtoxylin- and eosin-stained tissue sections
were first examined to localise areas of TCC. Fluorescence in situ
hybridisation sections were then scanned at  400 magnification
to localise the areas of interest. In total, three areas were identified
and in each area 20 nuclei were assessed. Chromosome 17 copy
number and HER2 copy number were assessed for each of the 20
nuclei at  1000 magnification. An average chromosome 17 copy
number and HER2/neu copy number was obtained totalling the
number of signals over the 60 nuclei and dividing by the number
of signals. Control sections of normal bladder and HER2/neu gene
amplified breast tumours were included in each run. The values for
disomy were derived from the analysis of normal bladder post-
mortem tissue, as previously assessed (Bartlett et al, 1998; Watters
et al, 2000). The average HER2/neu copy number was 1.7 (70.1)
and hence a HER2/neu copy number greater than 2 (1.7þ3 s.d.)
was defined as ‘increased’. The average chromosome 17 copy
number was 1.7 (70.06) and hence a polysomy 17 was defined as a
chromosome 17 copy number greater than 1.88 (1.7þ3 s.d.).
Gene amplification was defined as an HER2/Chromosome 17 ratio
of greater than 2 (Bartlett, 2001), based on the value used in breast
cancer diagnostics.
Immunohistochemistry
Antigen retrieval was performed by placing the slides in a pressure
cooker containing 1l of boiling water with 0.37g (1 10–3moles)
of ethylenediaminetetracetic acid (EDTA). The pressure cooker
was placed in a microwave (850W) for 13.5min, then the lid was
removed and the slides were left to stand for another 20min. The
slides were then loaded onto an automated machine (NEXUS II,
Ventana USA) with a rotating slide carousel. The following
reagents were added in sequence automatically by the machine
(all steps were performed at 371C, and reagents were purchased
prepacked): (1) 0.1ml of inhibitor (containing 1.1% hydrogen
peroxide, which is metabolised by endogenous peroxidase), for
4min; (2) 100ml (0.63gml
 1) of CB11 monoclonal primary
antibody (IgG 1); (3) 0.1ml each of amplifier A (IgG heavy and
light chains) and B (IgG heavy chains) for 8min. This binds to the
previously bound primary antibody, increasing the number of
antibodies at the site of the antigen, thereby increasing staining
intensity; (4) 0.1ml of biotinylated secondary antibody (IgG) for
8min; (5) 0.1ml of avidin-HRPO conjugate (horseradish perox-
idase), which binds to the biotin, for 8min; (6) 0.1ml of
diaminobenzidine (DAB) for 8min. This chromagen produces a
brown precipitate at the sites of the avidin–biotin reaction; (7)
0.1ml of copper sulphate to enhance the brown precipitate; (8)
0.1ml of haematoxylin and 0.1ml of bluing agent containing
lithium carbonate to stain the nuclei blue. The slides were then
dehydrated through graded alcohols and mounted and fixed with
xylene and DPX. Normal bladder tissue controls and breast
cancers with HER2/neu gene amplification and strong protein
overexpression were used as controls in each run.
Scoring
Representative areas were identified from the H&E sections and
corresponding areas were scored using a conventional light
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ymicroscope. Only membrane staining was scored, with cytoplasmic
staining being ignored. A 4-point scale was used: ‘0’ if there was no
membrane staining, ‘1’ if there was weak membrane staining in at
least 10% of cells, ‘2’ if there was moderate membrane staining in
at least 10% of cells, ‘3’ if there was strong membrane staining in at
least 10% of cells.
RESULTS
Patients
The average age of the patients was 71.3 years (range 43–92) and
there were 20 male and five female patients. The average time to
progression from preinvasive disease was 20.6 months (range 2–
90). There was one postoperative death, eight patients were still
alive and 16 (16/25, 64% had died from their disease. The average
survival from the time of the diagnosis of muscle-invasive disease
to death was 9.9 months (range 1–57). In the majority of cases
detrusor muscle invasion was preceded by either a pT1G3 (13 out
of 26 cases) or a pTaG2 (10/26 cases) tumour. Tables 1a and 1b
give the stages and grades of the tumours, the FISH and IHC
results as well as the times to progression.
Fluorescence in situ hybridisation
The average HER2/neu copy number for the preinvasive tumours
was 3.34 (range 1.73–18.30) and 3.48 for the postinvasive tumours
(range 1.90–8.50), and these were not statistically different
(P¼0.086). Overall, 19 out of 25 (76%) of the preinvasive and 23
out of 25 (92%) of the postinvasive tumours had an increased
HER2/neu copy number. The average chromosome 17 copy
number for the preinvasive group was 2.58 (range 1.74–3.68)
and 3.16 (range 1.62–8.48) for the postinvasive group, and again
these were not statistically different (P¼0.067). Overall 23 out of
25 (92%) of the preinvasive group and 24 out of 25 (96%) of the
postinvasive group were polysomic for chromosome 17. The
average HER2/chromosome 17 ratio in the preinvasive group was
1.34 and 1.17 in the postinvasive group; these values were not
statistically different (P¼0.31). These results are summarised in
Table 2. Two tumours out of both the pre- and postinvasive groups
were amplified for HER2/neu, representing three patients in total.
The stages and grades of these four tumours are given in Table 4.
Immunohistochemistry
In all, 19 (19 out of 25, 76%), of the preinvasive tumours and 13
(52%) of the postinvasive tumours were ‘positive’ for HER2/neu
protein overexpression and therefore six (six out of 25, 24%) of the
preinvasive and 12 (48%) of the postinvasive tumours were
‘negative’ (Table 3).
DISCUSSION
Contemporary models of bladder TCC progression suggest that
tumours of a higher stage and grade have accumulated more
genetic changes (Simon et al, 1998). It is thought that genetic
changes occur in sequence, such that certain genetic changes are
more common in pT2 compared with pTa/T1 tumours (Sauter et al,
1998). In the study by Simon et al (1998), the overall average
number of genetic aberrations in pT1 tumours was 9.8, in
comparison with 3.7 in pTa tumours, a statistically significant
difference (Po0.01). The authors concluded that these two tumour
groups are very different, both genetically and in terms of clinical
behaviour, with the pT1 tumours more likely to progress to
detrusor muscle-invasive disease than the pTa tumours, which did
not progress. In the present study, there were 11 pTa and 14p T1
tumours (Tables 1a and 1b), but in contrast to the study by Simon
et al, all the tumours in this study progressed to detrusor muscle
invasion. Table 2 compares the pTa tumours with the pT1 tumours
in terms of HER2 copy number, chromosome 17 copy number and
protein overexpression, demonstrating that they were not statis-
tically different. This suggests that the subgroup of pTa tumours
that are genetically different from pT1 tumours, as suggested by
Simon et al, are those that are unlikely to progress to pT2 disease.
However, in the present study, all the pTa/pT1 tumours progressed
to pT2 disease and as such had a completely different clinical
course. Hence, in terms of tumour progression, tumour stage and
grade (Table 4) appear to be less important than the actual genetic
changes that a tumour has accumulated. This study suggests that
Table 1a The HER2/chromosome 17 ratio, HER2 copy number,
chromosome 17 copy number, IHC score and time to progression in
months for all 26 tumour pairs
Patient
number
HER2/
chromosome
17 ratio
Chromosome
17 copy
number
HER2
copy
number
IHC
score
Time to
progression
(months)
1a 1.06 2.75 2.89 ‘3’ 13
1b 1.25 3.48 4.33 ‘3’
2a 1 1.74 1.73 ‘3’ 62
2b 1.17 1.93 2.25 ‘2’
3a 1.21 3.86 4.68 ‘2’ 9
3b 1.16 3.41 4.03 ‘1’
4a 1.13 2.33 2.6 ‘3’ 3
4b 1.51 3.19 4.97 ‘3’
5a 1.02 1.83 1.87 ‘3’ 38
5b 1.06 1.81 1.9 ‘0’
6a 1.09 1.98 2.14 ‘3’ 2
6b 1.5 2.13 3.17 ‘3’
7a 1.09 3.49 3.83 ‘3’ 3
7b 0.98 2.96 2.93 ‘2’
8a 0.82 3.28 2.61 ‘3’ 19
8b 1 8.48 8.5 ‘3’
9a 0.95 2.22 2.09 ‘2’ 32
9b 1.07 2.08 2.21 ‘1’
10a 1.06 2.77 2.9 ‘2’ 10
10b 0.83 2.51 2 ‘0’
11a 0.92 2.35 2.15 ‘3’ 4
11b 0.96 2.63 2.49 ‘3’
12a 0.91 2.7 2.47 ‘3’ 42
12b 0.98 3.15 3.07 ‘3’
13a 0.78 3.26 2.5 ‘3’ 12
13b 0.88 2.78 2.4 ‘3’
14a 0.96 3.39 3.24 ‘3’ 17
14b 0.9 3.43 3.08 ‘3’
15a 2.18 2.9 6.33 ‘3’ 6
15b 2.09 3.01 6.2 ‘3’
16a 1.14 2.43 2.74 ‘1’ 5
16b 1.48 4.7 7.04 ‘0’
17a 8.07 2.3 18.3 ‘3’ 26
17b 1.45 2.26 3.17 ‘0’
18a 0.96 1.91 1.82 ‘0’ 3
18b 2.02 1.62 3.2 ‘0’
19a 1.11 2.26 2.54 ‘0’ 3
19b 1.06 3.89 4.07 ‘0’
20a 0.98 1.97 1.93 ‘0’ 90
20b 1.33 3.43 2.58 ‘0’
21a 1.02 1.91 1.94 ‘0’ 10
21b 0.99 2.01 1.98 ‘0’
22a 1.04 2.13 2.21 ‘2’ 55
22b 1.06 3.69 3.79 ‘3’
23a 1.05 2.2 2.33 ‘3’ 6
23b 1.06 2.16 2.29 ‘3’
24a 1.07 3.62 3.8 ‘3’ 15
24b 0.96 2.98 2.86 ‘0’
25a 0.95 1.84 1.75 ‘0’ 31
25b 0.69 5.5 3.83 ‘0’
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ythose tumours that progress to pT2 disease have acquired
significant HER2/neu abnormalities before muscle invasion.
Oncogene activation is thought to occur late, and most genetic
changes are thought to occur before disease progression (Tsao et al,
2000). It therefore appears that in tumours that progress to pT2
disease have already acquired HER2/neu abnormalities that occur
before the onset of detrusor muscle invasion.
Gene amplification rates were low, being present in 8% of both
tumour groups, a value similar to previously published rates of 7
and 9% (Sauter et al, 1993; Underwood et al, 1995). The results are
also similar to those recently published by our group where
polysomy c-myc and CCND1 rates were higher than gene
amplification rates (Watters et al, 2002). Polysomy has been
shown to occur independently of tumour polyploidy and is not
only chromosome specific but also closely related to tumour
progression (Watters et al, 2002).
High levels of HER2/neu protein overexpression were also
observed, with rates of 76 and 52% present in pTa/T1 and pT2
tumours, respectively. These values were not significantly different
(P¼0.06), again suggesting that high level protein overexpression
occurs before tumour progression. It has been suggested that
either transcriptional or post-transcriptional mechanisms are
responsible for the observed difference between protein over-
expression and gene amplification. This phenomenon has also
been observed in breast cancers. In one study, 22 out of 79 (29%)
of breast cancers had HER2/neu protein overexpression without
HER2/neu gene amplification (Farabegoli et al, 1999). In a previous
study by Sauter et al (1993), 89% of bladder tumours with HER2/
neu protein overexpression did not have gene amplification,
results which are similar to the present study. Transcription rates,
and hence HER2/neu protein expression are controlled by nuclear
concentrations of the transcription factors such as GATA-3 and
OB2-1 (Shiga et al, 1993; Hollywood and Hurst, 1995). Higher
levels of such transcription factors, even in the absence of gene
amplification, result in increased HER2/neu protein overexpres-
sion. Stomach cancer cell lines SNU-1 and SNU-16 have similar
HER2/neu transcription rates with similar mRNA concentrations,
but the SNU-1 cells express the HER2/neu protein at a higher level
than the SNU-16 cells. This is due to preferential translation of the
mRNA from the SNU-1 cells (Bae et al, 2001).
Anti-HER2/neu therapy has been used to treat breast cancers in
a clinical setting with encouraging results. Herceptin is a
monoclonal antibody directed against the HER2/neu protein,
which has an antimitotic and antiangiogeneic effect on tumours
cells. In breast cancer, response rates have been highest in tumours
that have strong protein overexpression (which are also gene
amplified). Overall response rates of 50% have been observed
(Slamon et al, 2001). Furthermore, synergism has been demon-
strated between Herceptin and conventional chemotherpeutic
agents like cisplatin (Baselga, 2001). The high rates of strong
(‘3þ’) protein overexpression rates in the pTa/T1 tumours 60%,
together with the high rates of polysomy 17 and increased
HER2/neu copy number suggests that Herceptin might also be of
value in the treatment of TCC. In particular, the application of
anti-HER2/neu therapy to pTa or pT1 tumours that are most
likely to progress to pT2 disease, based upon the presence of
increased HER2 copy number, polysomy 17 and increased HER2/
neu protein overexpression might lower the rate of disease
progression.
Table 1b Stage and grade distribution of the 25 pairs of tumours
G3 pT2 G2 pT2 G3 pT4 G2 pTa G3 pT1 G1 pTa G1 pT1 G2 pT1
Preinvasive 10 12 1 1 1
Postinvasive 22 1 2
The table illustrates that most (23/2523/26) of the postinvasive tumours were G3 pT2, and there were 11 pTa and 14 pT1 tumours in the preinvasive group.
Table 2 Mean HER2 copy number, chromososme 17 copy number and HER2/chromosome 17 copy ratio in the pTa and p T1 tumours
Mean HER2
copy number (range)
Mean chromosome
17 copy number (range)
Mean HER2/chromosome 17
ratio (range)
pTa 3.34 2.58 1.34
(n¼11) (1.7–18.3) (1.74–3.68) (082–2.18)
pT1 3.53 3.16 1.17
(N¼15) (1.9–8.5) (1.62–8.48) (0.91–8.07)
There was no difference in the rates of polysomy 17 (P¼0.21), HER2/neu copy number (P¼0.34) or HER2/chromosome 17 (P¼0.44) ratio between the pTa and pT1
tumours.
Table 3 Values for the HER2 immunohistochemistry results
‘0’ ‘1+’ ‘2+’ ‘3+’
Preinvasive 5 1 4 15
Postinvasive 10 2 2 11
The HER2 immunohistochemistry results for the 25 pairs of patients. Both ‘2+’ and
‘3+’ were considered positive and ‘0’ and ‘1+’ were considered negative. In total, 19
out of 25 76% of the preinvasive tumours were positive. The level of protein
overexpression was less in the postinvasive tumours (13 out of 26, 50%).
Table 4 Stage and grade details of the four gene amplified tumours,
together with FISH results
Tumour
stage/grade
HER2
copy number
Chromosome 17
copy number
HER2/
chromosome 17
G2 pTa 6.33 2.99 2.18
G3 pT2 6.2 3.01 2.09
G3 pT1 18.3 2.3 8.07
G3 pT2 3.22 1.6 2.01
The tumours with HER2/chromosome 17 ratios of 2.18 and 2.09 are from the same
patient, suggesting that gene amplification is present before the onset of muscle
invasion and persists. The preinvasive G3 pT1 tumour with the highest level of
amplification had a postinvasive HER2/chromosome 17 ratio of 1.45. The
postinvasive G3 pT2 tumour with borderline gene amplification of 2.01 had a
preinvasive HER2/chromosome 17 ratio of 0.96.
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